1240997-07-2Relevant academic research and scientific papers
PHARMACEUTICAL COMPOSITIONS
-
Page/Page column 46, (2010/09/05)
Microemulsions of pharmaceutical compositions comprising, the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers, forming organized structures as: aggr
Tricyclic condensed pyrazole derivatives as CB1 inhibitors
-
Page/Page column 59, (2010/09/17)
Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring rcomprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous sy
Tricyclic pyrazole derivatives and microemulsions thereof as CB1- and/or CB2-inhibitors
-
Page/Page column 64, (2010/09/17)
Microemulsions of pharmaceutical compositions comprising the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers forming organized structures as: aggreg
PHARMACEUTICAL COMPOUNDS
-
, (2010/09/05)
Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.
